{"groups":[{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG000","title":"RDT Cohort - Castration-Resistant Prostate Cancer (CRPC)"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG001","title":"RDT Cohort - Melanoma"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG002","title":"RDT Cohort - Non-Small Cell Lung Cancer (NSCLC)"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG003","title":"RDT Cohort - Pancreatic Cancer"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG004","title":"RDT Cohort - Gastric/Gastroesophageal Junction Cancer (GEJ)"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG005","title":"RDT Cohort - Hepatocellular Carcinoma (HCC)"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG006","title":"RDT Cohort - Small Cell Lung Cancer (SCLC)"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG007","title":"RDT Cohort - Ovarian Cancer"},{"description":"Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).","id":"FG008","title":"RDT Cohort - Metastatic Breast Cancer (MBC)"},{"description":"Subjects received a single oral daily dose of cabozantinib at 100 mg.","id":"FG009","title":"NRE Cohort - CRPC 100 mg"},{"description":"Subjects received a single oral daily dose of cabozantinib at 39.4 mg.","id":"FG010","title":"NRE Cohort - CRPC 39.4 mg"},{"description":"Subjects received a single oral daily dose of cabozantinib at 100 mg.","id":"FG011","title":"NRE Cohort - Ovarian Cancer 100mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"171"},{"groupId":"FG001","numSubjects":"77"},{"groupId":"FG002","numSubjects":"60"},{"groupId":"FG003","numSubjects":"20"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"41"},{"groupId":"FG006","numSubjects":"21"},{"groupId":"FG007","numSubjects":"70"},{"groupId":"FG008","numSubjects":"45"},{"groupId":"FG009","numSubjects":"93"},{"groupId":"FG010","numSubjects":"51"},{"groupId":"FG011","numSubjects":"60"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"47"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"19"},{"groupId":"FG005","numSubjects":"36"},{"groupId":"FG006","numSubjects":"20"},{"groupId":"FG007","numSubjects":"60"},{"groupId":"FG008","numSubjects":"41"},{"groupId":"FG009","numSubjects":"87"},{"groupId":"FG010","numSubjects":"48"},{"groupId":"FG011","numSubjects":"54"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}